Roivant Sciences Ltd. (ROIV)
| Bid | 10.15 |
| Market Cap | 7.27B |
| Revenue (ttm) | 97.56M |
| Net Income (ttm) | -116.62M |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -10.19 |
| Forward PE | -11.28 |
| Analyst | Buy |
| Ask | 10.71 |
| Volume | 4,597,994 |
| Avg. Volume (20D) | 5,920,093 |
| Open | 10.07 |
| Previous Close | 9.86 |
| Day's Range | 9.87 - 10.26 |
| 52-Week Range | 8.73 - 13.05 |
| Beta | 1.25 |
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aur...
Analyst Forecast
According to 4 analyst ratings, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 76.56% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatme...
